Egis Pharmaceuticals PLC

egis.hu

Egis Pharmaceuticals PLC, headquartered in Budapest, Hungary, is one of the leading pharmaceutical companies operating principally in Central and Eastern Europe, Russia and the CIS region. Our history dates back to more than a century and our activities extend to every field of the pharmaceutical value chain: from R&D through the production of APIs and FPs to sales and marketing. Our products ranging from tablets to injections and galenic products are sold in almost 60 countries worldwide. Besides Hungary we sell our products under the brand name Egis in 17 countries through our network of subsidiaries and representative offices.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SALESFORCE LAUNCHES NEW HYBRID CMS PLATFORM 'SALESFORCE CMS’

DECK 7 | February 04, 2020

news image

Demand owns content, and with the release of 'Salesforce CMS', it’s clear that Salesforce is putting the control squarely with demand, not to mention delighting the creative marketer with more power through additional tools for creating content that are expected to work well right out of the box (er… cloud). Customers have become accustomed to consuming content across multiple channels and platforms which requires marketers to provide for seamless integration of their conten...

Read More

PHARMACY MARKET

KROMATID ANNOUNCES LAUNCH OF KROMATID PINPOINT FISH TP53/CEP17 KIT FOR SYNTHETIC OLIGONUCLEOTIDE-BASED FISH ASSAY

KromaTiD Inc | January 14, 2022

news image

KromaTiD is excited to announce early access to our KromaTiD Pinpoint FISH TP53/CEP17 Kit, our new product designed to supply the highest resolution, lowest background, and lowest limit of detection available. KromaTiD's Pinpoint FISH™ Kit, allows for better hybridization conditions and eliminating strand degradation steps. Pinpoint FISH™ allows researchers to expand beyond the capabilities of conventional FISH probes to detect smaller targets and design ultra-high...

Read More

FIXX PHARMACEUTICALS WANTS TO DOMINATE HEMOPHILIA MARKET WITH GENE EDITING

Prnewswire | August 28, 2020

news image

Fixx Pharmaceuticals Inc. is pleased to announce the launch of its biotechnology business operations in Las Vegas, Nevada and San Francisco, California. The company is focused on developing a cure for Hemophilia through the use of CRISPR gene editing. There are currently 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally. "We are looking to commercialize a product as soon as possible," says Jesse John Francis Clark, founder of Fixx. "We are going to develop ...

Read More

BUSINESS INSIGHTS

INNOCOLL ANNOUNCES PUBLICATION OF POSITIVE RESULTS FROM PIVOTAL CLINICAL TRIAL OF POSIMIR IN ARTHROSCOPIC SUBACROMIAL DECOMPRESSION

Innocoll Pharmaceuticals | July 07, 2022

news image

Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, announced the publication of the results of Study BU-002-IM evaluating the safety and efficacy of POSIMIR® for infiltration use in 107 patients undergoing arthroscopic subacromial decompression. The peer-reviewed paper, entitled “SABER-Bupivacaine Reduces Postoperative Pain and Opioid Consumption After Arthroscopic Subacromial Decompression: A Randomized, Placebo-C...

Read More
news image

SALESFORCE LAUNCHES NEW HYBRID CMS PLATFORM 'SALESFORCE CMS’

DECK 7 | February 04, 2020

Demand owns content, and with the release of 'Salesforce CMS', it’s clear that Salesforce is putting the control squarely with demand, not to mention delighting the creative marketer with more power through additional tools for creating content that are expected to work well right out of the box (er… cloud). Customers have become accustomed to consuming content across multiple channels and platforms which requires marketers to provide for seamless integration of their conten...

Read More
news image

PHARMACY MARKET

KROMATID ANNOUNCES LAUNCH OF KROMATID PINPOINT FISH TP53/CEP17 KIT FOR SYNTHETIC OLIGONUCLEOTIDE-BASED FISH ASSAY

KromaTiD Inc | January 14, 2022

KromaTiD is excited to announce early access to our KromaTiD Pinpoint FISH TP53/CEP17 Kit, our new product designed to supply the highest resolution, lowest background, and lowest limit of detection available. KromaTiD's Pinpoint FISH™ Kit, allows for better hybridization conditions and eliminating strand degradation steps. Pinpoint FISH™ allows researchers to expand beyond the capabilities of conventional FISH probes to detect smaller targets and design ultra-high...

Read More
news image

FIXX PHARMACEUTICALS WANTS TO DOMINATE HEMOPHILIA MARKET WITH GENE EDITING

Prnewswire | August 28, 2020

Fixx Pharmaceuticals Inc. is pleased to announce the launch of its biotechnology business operations in Las Vegas, Nevada and San Francisco, California. The company is focused on developing a cure for Hemophilia through the use of CRISPR gene editing. There are currently 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally. "We are looking to commercialize a product as soon as possible," says Jesse John Francis Clark, founder of Fixx. "We are going to develop ...

Read More
news image

BUSINESS INSIGHTS

INNOCOLL ANNOUNCES PUBLICATION OF POSITIVE RESULTS FROM PIVOTAL CLINICAL TRIAL OF POSIMIR IN ARTHROSCOPIC SUBACROMIAL DECOMPRESSION

Innocoll Pharmaceuticals | July 07, 2022

Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, announced the publication of the results of Study BU-002-IM evaluating the safety and efficacy of POSIMIR® for infiltration use in 107 patients undergoing arthroscopic subacromial decompression. The peer-reviewed paper, entitled “SABER-Bupivacaine Reduces Postoperative Pain and Opioid Consumption After Arthroscopic Subacromial Decompression: A Randomized, Placebo-C...

Read More